Von Willebrand Disease (VWD) is a bleeding disorder where blood doesn't clot well. This study is investigating a new treatment called subcutaneous VGA039, which is given under the skin to help prevent bleeding in people with VWD. The study will last for about 73 weeks in total, with a 24-week observation period where no treatment is given, followed by 49 weeks of treatment with VGA039.

During the study, participants will keep track of any bleeds they have and the treatments they use in a diary. The study will also monitor for any side effects or adverse events throughout the study period.

• The study requires participants to be aged 12 to 75 years.
• The study involves a total time commitment of approximately 73 weeks.
• Participants need to have a history of ≥12 bleeding episodes per year.

To join, potential participants must not have used certain VWF treatments in the last 6 months and should not have other serious health issues like heart disease or blood clotting problems. This study helps researchers understand if VGA039 is a safe and effective treatment for preventing bleeds in VWD patients.